Barbara Duncan

Barbara serves on the board of directors of Versanis Bio, Adaptimmune Therapeutics plc, Jounce Therapeutics, Inc., Area Pharmaceuticals, Inc., Fusion Pharmaceuticals, Inc., and Ovid Therpaeutics. She previously was the chief financial officer and treasurer at Intercept Pharmaceuticals Inc. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical Inc., including chief financial officer, and ultimately, was chief executive officer prior to DOV’s sale to Euthymics Bioscience Inc. in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read Inc. and Lehman Brothers Inc.

Ms. Duncan received her Bachelor of Science from Louisiana State University and her Master of Business Administration from the Wharton School of the University of Pennsylvania.